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2Introduction
Anticoagulation therapy is well established, yet as a long-term therapy 
optimal management of patients can be challenging. The impact of excellent 
anticoagulation services on population health and reduction of budget 
pressure is significant, but is there consensus on the best care pathway for 
patients on anticoagulants? How can patients be supported and optimally 
managed?
This collaborative discussion paper explores a series of questions in relation 
to optimal anticoagulation management for patients on direct oral 
anticoagulants (DOACs – also known as new/novel oral anticoagulants or 
NOACs). 
The paper will examine:
• Patient choice in anticoagulation therapy
• DOACs in anticoagulation therapy today
• The official advice for excellent anticoagulation services
• Is there a consensus on a standardised process for DOACs?
• Adherence in DOACs anticoagulation therapy
• The importance of education in a patient-centred approach to long-term 
anticoagulation therapy
• Initiatives to support adherence for patients on DOACs
Under the guidance of the contributors, the paper gathers questions regarding 
the current and future issues of anticoagulation therapy, with particular focus 
on DOACs. It also explores what initiatives have been put in place to perfect 
anticoagulation management, including working with local pharmacies and 
nurse-led anticoagulation clinics in primary care. 
This paper includes feedback and views from opinion leaders in 
anticoagulation to prompt a wider discussion on potential areas for 
development in anticoagulation management for patients on DOACs.  
3Editor’s note
Being diagnosed with a long-term condition can be daunting – whether it is 
the result of a years-long search, an admission to hospital or a routine check-
up. People are often at their most vulnerable when consulting their care team 
in search for an explanation, and even a solution, for something which already 
affects their lives. They want to feel listened to, consulted and supported. They 
want reassurance that any therapy or treatment takes into account their needs 
and adapts to the requirements of their lives whilst offering them the best 
available care. 
We aim to start an informed debate on how this can be can achieved for 
patients in long-term anticoagulation therapy. Under the guidance of our 
advisors and with the expert insight of our contributors, this collaborative paper 
examines best practice and collates unanswered questions about the future of 
anticoagulation therapy.
Let us highlight some of the great efforts being made to support people on 
anticoagulation therapy and discuss what else can be done to achieve 
excellent management.
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Patient choice in 
anticoagulation therapy
5
Anticoagulation 
therapy today
Section 1
The group of conditions requiring anticoagulation therapy include 
venous thromboembolism (VTE), stroke prevention for non-valvular atrial 
fi brillation and prosthetic heart valves. Usually started in secondary 
care or outreach clinics in primary care1, anticoagulation therapy offers 
patients a choice between 5 usual medication types: warfarin, apixaban, 
dabigatran, edoxaban and rivaroxaban2.
Warfarin is considered a cost-effective drug for anticoagulation 
therapy. However, although costs have been perceived as a barrier, the 
National Institute for Health and Care Excellence (NICE) has concluded 
that DOACs are also cost-effective when the medical, societal and 
personal savings from avoiding strokes are taken into account. These 
anticoagulants must then be available to patients within their licensed 
indications.3,4
In the case of DOACs, NICE suggests that although there is no need 
for regular blood tests to check their international normalised ratio 
(INR), patients still require regular follow-up and monitoring5. As the 
anticoagulant effect of the DOACs decreases 12–24 hours after the 
last dose is taken, NICE also highlights the importance of adherence to 
reduce the risk of a thromboembolic event6.
For all anticoagulants it is recommended that patients are fully involved 
in the decision making about their treatment. Comprehensive education, 
decision support materials and an informed discussion of the benefi ts 
and side effects of each medication should be part of the initial 
consultation. An ongoing package of monitoring, reviews and support 
should also be agreed upon between patient and care team.7
6“(…) although (unlike 
warfarin) there is no need 
to have regular blood tests 
to monitor the international 
normalized ratio (INR), they 
[patients on DOACs] will still 
require regular monitoring, 
blood tests, and review of 
their treatment.”5
DOACs in anticoagulation 
therapy today
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DOACs present potential advantages in fixed dosing, fewer drug interactions 
and fewer clinic appointments as compared to warfarin, which for years has 
been the standard of care for anticoagulation therapy. The prescribing trends 
for DOACs have shown an accelerated increase in the last couple of years8 
and this is estimated to continue. Sue Rhodes, VTE CNS and joint Anticoagulant 
Lead at Great Western Hospital in Swindon, describes that the trend “continues 
to rise with the national average being a year-on-year increase of 10–11%.” 
However, some experts argue that the uptake has been lower and slower 
than expected. In England, the uptake of DOACs varies from 4.2% to 69.3% 
across CCGs9 and in 2015, the average uptake was 16.5%, 3.5% lower than the 
20% estimated for the first year9. Prof John Camm from St George’s University 
Hospital, highlights that the perceived costs, the lack of monitoring and the 
choice between four different agents might be initial deterrents slowing the 
uptake. Nevertheless, the clear net clinical benefit of DOACs, he explains – as 
well as an improved quality of life for patients – should drive a faster increase 
in their use. Prof Camm also explains that long-term therapy is cost-effective 
and that “the costs of the DOACs are falling very quickly and this reduction 
will continue especially as the indications for lifelong therapy with these drugs 
increase”.
warfarin forecast DOAC’s forecast
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Public Health England, April 2016.8
8NICE and the European Heart Rhythm Association (EHRA) provide 
recommendations for the use of DOACs in anticoagulation therapy. As an 
example, the EHRA suggests that treatment of patients on DOACs should 
be reviewed once every 3 months and that regular reviews must assess 
adherence, any event that might signal thromboembolism, adverse effects, 
co-medication and renal and hepatic function10. The implementation of 
advice around DOACs, however, is not optimal and consensus is still yet to be 
achieved about what would represent excellence in DOACs anticoagulation 
management, including adherence.
A report called ‘One Year On: Why are patients still having unnecessary AF-
related strokes?’11, reviews the implementation of the guideline from NICE 
(CG180) clinical guidance for Atrial Fibrillation (AF) management12 one year 
after guidance publication. This report determined that “around half of patients 
that should be treated with oral anticoagulation are not.”13 NICE has estimated 
that implementing the CG180 for people with AF – the most common heart 
arrhythmia with an incidence expected to double in the next 50 years14,15  – 
can result in 10,000 fewer strokes per year, reducing the risk of stroke by 31%14.
Optimal anticoagulation management can have an immeasurable impact on 
the lives of patients and their loved ones as well as a significant impact on the 
NHS with reductions in adverse events and improvement in cost-effective care. 
But how can excellent anticoagulation management be achieved?
“around half of patients that should be 
treated with oral anticoagulation are not.”13
9Long-term therapies: a problem 
with adherence?
Adherence in 
long-term therapies
Section 2
Compliance is defi ned as the “action or fact of complying to a wish 
or command”16. Adherence, on the other hand, implies an agreement 
between the patient and the prescriber on the latter’s recommendations 
and is defi ned by the degree to which a patient’s actions follow this 
agreement17. Understanding the patient as an active partner and 
striving for good communication between them and their care team is 
necessary for effective clinical practice18.
Adherence in long-term conditions can be a challenge. It is estimated 
that between a third and a half of medicines prescribed for these 
conditions are not taken as recommended17. Studies have found that 
adherence to long-term therapy or treatment can average 50%19,20. 
Non-adherence represents a fundamental limitation in the delivery 
of healthcare which might result from a failure to fully agree with the 
patient on their treatment and to identify and provide the necessary 
support they will need later on17. Non-adherence can result in a lack 
of improvement or deterioration of health, as it limits the benefi ts of 
medicines generating an increased demand on the healthcare system 
from deteriorating population health17.
The causes of non-adherence have been described in two overlapping 
categories: intentional and unintentional17. These are their defi nitions:
• Unintentional non-adherence – “occurs when the patient wants 
to follow the agreed treatment but is prevented from doing so by 
barriers that are beyond their control.”17 Examples include problems 
using the treatment, forgetting to take it and diffi culty understanding 
the instructions.17
10
Adherence in long-term 
conditions can be a 
challenge. It is estimated 
that between a third 
and a half of medicines 
prescribed for these 
conditions are not taken as 
recommended17. Studies 
have found that adherence 
to long-term conditions can 
average 50%19,20.
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• Intentional non-adherence – “occurs when the patient decides not to 
follow the treatment recommendations.”17 This can happen when the 
patient’s beliefs and preferences don’t align with the treatment, affecting 
their motivation to start and continue with it.17 As an example, some 
patients are wary of becoming dependant on their medication, especially 
on long-term therapies21. 
Adherence can also be affected by: 21
• The complexity of the treatment – number of medicines and frequency of 
administration
• Social/economic factors – including medication costs
• Condition-related factors – such as the level of disability and the severity of 
the condition
 
In order to support adherence through the intrinsic complexities of long-term 
therapies, it is important that healthcare professionals find the most effective 
way of communicating with patients and also facilitate an environment of 
involvement and support17. This must start at diagnosis and initial prescriptions, 
but it ought to continue throughout treatment to minimise the effect of non-
adherence as a fundamental limitation in the delivery of the healthcare 
system17. 
Understanding the patient as an active partner, taking into account their 
preferences and enabling them to make informed decisions whilst striving 
for good communication with their care team is essential for effective clinical 
practice.17 An open, patient-centred approach that avoids focussing on 
blame and recognises non-adherence as a common issue, should encourage 
patients to be frank about their experience and to raise any doubts or 
concerns they have about treatment. Working with such an approach, care 
teams can identify specific, perceptual and practical adherence barriers for 
each individual on an ongoing basis22. 
Jo Jerrome, CEO Thrombosis UK, explains the importance of a positive 
exchange between a healthcare professional and patient from the latter’s 
perspective:
“Understanding your condition and treatment are key factors in helping to 
restore health and well-being. To be able to try to restore your life, you need 
to feel confident that you’re in “safe hands” – that your care is monitored and 
responsive to you and your medical needs. This is especially critical when 
managing long-term conditions often requiring multiple healthcare providers. 
Nothing feels better than being able to leave a medical appointment reassured 
12
of the care, sharing of information, treatment and planned monitoring that will 
keep you well and as safe as possible.”
As highlighted in this quote, one of the pillars of excellent care is essential 
communication between healthcare professionals and patients. This creates a 
strong partnership supported by evidence-based information which takes into 
account the patient’s needs and preferences for their treatment and care. 23
Adherence can 
also be affected by: 21
Complexity of the treatment 
– number of medicines and frequency of 
administration
Social/economic factors 
– including medication costs
Condition-related factors 
– such as the level of disability/severity of the 
condition
Recommendations for excellent 
anticoagulation services
Excellent  
anticoagulation 
services
Section 3
Effective anticoagulation therapy can reduce the risk of strokes, save lives 
and reduce costs related to long hospital stays, lower rates of discharge 
and severe stroke-related complications for the NHS.24 Ensuring the best 
provision of care can have a signifi cant impact on population health 
across the UK.
What does excellence in anticoagulation 
services involve?
The Interdisciplinary group for Stroke Prevention in Atrial Fibrillation (iSPAF) 
put forward a paper called ‘Excellence in anticoagulation care: Defi ning 
the elements of an excellent anticoagulation service’ from an in-depth 
review of best practice guidelines and examples as well as clinical 
evidence related to AF care. Consistent with most of the existing advice, 
and largely transferable to anticoagulation therapy for other conditions, 
the recommendations of this document describe that excellent 
anticoagulation services should include: 4,25 
• Comprehensive patient education
• Clear protocols of patient initiation, performance and reassessment
• Regular patient and medication reviews
• Alternative treatment options where required
• Multidisciplinary expert care
• A clear and simple electronic referral pathway
• Provision of regular and transparent performance data to 
commissioners and patients
High quality anticoagulation care will meet the patient’s lifestyle needs, 
will integrate care across secondary and primary – especially for 
complex patients – and will be delivered accessibly and close to home.7 
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A one-stop anticoagulation service will include patient education, discussion 
and support as well as blood tests, dose changes and follow-up arrangements 
to help manage the patient’s care.26
Shared decision making 
The factors that affect patients’ decisions about medicines include their 
understanding of their condition, the view of their own need for the treatment, 
their concerns about the medicine and their awareness of the possible 
treatments27. The active involvement of patients in anticoagulation therapy 
is highly important and should take place not only during initiation but 
throughout the management of their medication and the evolution of their 
condition. In order to enhance adherence, it is important to sustain the level of 
involvement of patients – especially those who have long-term conditions – to 
promote a continuous understanding of their anticoagulation medication and 
the importance and benefi ts of adherence.
Expert advice suggests that excellent anticoagulation services should be 
built around the needs of their patient populations and offer informed initial 
consultations on:26 
• The patient’s condition
• The medical aims of anticoagulation therapy
• An overview of all the available anticoagulant options, how they will 
inﬂ uence their conditions and what are their benefi ts and disadvantages 
A working partnership between patient and clinician is then established 
which ideally clarifi es what the patient hopes the treatment will achieve and 
avoids making assumptions about the patient’s preferences.27 Finally, through 
comprehensive education and decision support, they choose treatment and 
an ongoing package of monitoring, review, education and support.10
The process of informing and educating the patient is a continuous one. Their 
knowledge, understanding, views and concerns will change over time and that 
is why it is important to review them and offer repeat information whilst treating 
long-term conditions and multiple medicines.28 Effective treatment relationships 
rely on evidence-based explorations of the available therapeutic options, 
negotiations of the treatment, planned follow-up and informed discussions on 
adherence17.
14
Comprehensive patient 
education
Clear protocols of patient 
initiation, performance 
and reassessment
Regular patient and 
medication reviews
Alternative treatment 
options where required
Multidisciplinary 
expert care
A clear and simple 
electronic referral pathway
Regular and transparent 
performance data for 
commissioners and patients
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Excellent AC services 
should include: 4,25 
Structured monitoring and follow-up 
Inconsistent anticoagulation therapy can lead to worse outcomes and, in 
the case of patients with AF, it might be associated with a higher risk of stroke-
associated disability21. The AF Association, with a membership of over 30,000 
patients, is an organisation with a designated help and support line for patients 
with AF and it promotes effective care following the ‘Detect, Protect, Correct 
and Perfect’29 care pathway brought together in the AF Toolkit. To ensure that 
the available, proven and recommended guidance is implemented at primary 
care level, the AF Association focuses on the ‘Perfect the Patient Pathway’ 
working in partnership with multiple stakeholders at regional and national level 
in England and the devolved nations to drive the uptake and implementation 
of best practice.30
The AF Association explains that,
“It is critical that healthcare professionals work in partnership to manage 
patients with AF to ensure detection, appropriate anticoagulation therapy is 
prescribed, and specialist referral to appropriate treatment option for AF is given 
– however, without effective monitoring and follow-up this good work can still be 
tragically undone if patients do not adhere to anticoagulation therapy.”31 
The monitoring of warfarin anticoagulation therapy is well established and 
structured. Reliant on the INR, patients and clinicians should work together to 
aim for the target INR and assess the time in therapeutic range (TTR) with a 
minimum NICE recommended TTR of 65%.32 Self-testing and self-management 
are as effective and safe as usual care for suitable patients and can improve 
the quality of oral anticoagulation for this group.33
However, anticoagulation therapy is changing. DOACs with less drug 
interactions, fixed dosing, fewer visits to clinic and no need for routine 
coagulation monitoring, continue to rise in prescription numbers across 
England – sometimes quadrupling in a space of a few years such as the 
case of apixaban, edoxaban and rivaroxaban. But is there consensus on a 
standardised process for the management of patients on DOACs?
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A standardised process for 
DOACs
Best Practice for 
DOACs
Section 4
The ‘EHRA Practical Guide on the Use of New Oral Anticoagulants 
(NOAC) in Patients with Non-Valvular Atrial Fibrillation’ describes that 
structured follow-up is mandatory to ensure safe and effective drug 
intake. DOACs have a short half life and their therapeutic effect fades 
rapidly (12–24 hours after the last intake), compromising stroke/clot 
prevention. That is why all means to optimise anticoagulation therapy 
and medication adherence should be considered to support adequate 
protection. Alongside education, as for all anticoagulation therapy, the 
recommendation is that patient and care team agree on a clearly 
pre-specifi ed follow-up schedule which might include expert care 
from different disciplines such as a general practitioner, cardiologist or 
electrophysiologist.10 
NICE recommends patients on DOACs should be reviewed every 3 
months to:34
• Assess compliance to treatment and reinforce advice regarding the 
importance of a regular dosing schedule
• Enquire about or assess the presence of any adverse effects such as 
bleeding, symptoms of stroke or a VTE including pulmonary embolism
• Ask the person if they have been taking any other medicines 
including any bought over-the-counter
NICE highlights that there is concern that the lack of monitoring will 
lead to poor adherence on DOACS – where due to the relatively short 
half-lives of these drugs adherence is important35. NICE recommends 
that patients on DOACs still require regular monitoring, blood tests to 
determine kidney and liver function and review of their treatment36. 
Additionally, NICE describes that patients should have access to 
ongoing education and support where “healthcare professionals ensure 
that patients understand why they are taking an anticoagulant and the 
expected benefi ts”.37
18
1
Assess compliance 
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importance of a 
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presence of any 
adverse effects 
such as bleeding, 
symptoms of stroke 
or a VTE including 
pulmonary 
embolism
Ask the person 
if they have 
been taking any 
other medicines 
including any 
bought over-the-
counter
NICE recommends patients on DOACs 
should be reviewed every 3 months34
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Best practice and consensus
However, there are still questions about the implementation of the 
recommendations and whether there is consensus behind them. Our 
contributors raise some of them in this section.
Prof Camm explains, 
“NICE guidelines are confusing because of the need to balance the books 
and the inability of NICE to see how therapy will inevitably develop. The EHRA 
guidance is less confusing but deals with the details of the use of NOACs which 
is far too much for the primary care physician – a less complicated version of 
this kind of document for GPs is needed.”
Application of best practice and evidenced advice can vary across the UK 
and so does the access to life-saving treatment. A recent report by The Medical 
Technology Group called ‘The North-South NHS Divide: How where you are not 
what you need dictates your care’, found a vast range in admission rates for 
rapid treatment of stroke patients – which can make the difference between life 
and death: “from over eight out of ten patients being seen within this time [4 
hours of arrival] (84.5 per cent) in Hillingdon to just a fifth (21 per cent) in Wyre 
Forest.”38
At St George’s University Hospital, patients are receiving education from 
anticoagulation nurses and pharmacists. Prof Camm continues, 
“The workload for DOACs is no greater than for vitamin K antagonist (VKA) 
therapy, but since the initiation and follow-up of this therapy takes place in 
different locations the funding for this follow-up must also follow the patients. At 
my hospital, we use anticoagulation nurses and pharmacists to educate patients 
and they are also responsible for the primary follow-up of the anticoagulant 
therapy in patients with AF. This is more difficult in general practice. There are 
some solutions such as use of community pharmacists or practice nurses, but 
much of this depends on the size of the group practice. Small practices cannot 
implement these solutions and should probably opt to have their patients 
followed in secondary care.”
In a 2016 service audit, the Carmel Medical Practice, Darlington, identified a 
practice prevalence of AF of 2.7%39. From a total patient population of 272, 
treatment of patients on DOACs was 57.9% from which 92.4% had their U+E/
creatinine clearance level review in the past 12 months39,40. Prof Ahmet Fuat 
from the Carmel Medical Practice, believes that EHRA’s advice is the best 
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available and explained that his practice follows it: 
“I think monitoring of DOACs is essential and we have a 6-monthly rolling audit 
of all our AF patients. We obviously need to monitor time in therapeutic range 
for warfarin every 6-months. All patients need full blood count, renal function 
and liver function tests at least once a year. If they are over 75 and/or frail, 
we check these once every 6 months (especially if dabigatran or edoxaban, 
which are more reliant on renal clearance). We should use creatinine clearance 
calculated using the Cockcroft-Gault criteria, as this is what all trials use and 
I do not agree with NICE guidance stating eGFR should be used. In otherwise 
reasonably fit patients under 75 with normal renal function assessment 12 
monthly is enough.”
At Great Western Hospital, the anticoagulation service is following up patients 
regularly. Sue Rhodes explains that follow-up is dependent on three elements: 
location, current service provision and system capacity to provide appropriate 
advice and carry out follow-up. She describes:
“Our service is predominantly secondary care led and we have incorporated 
the DOAC patients into our existing database so that we can follow them up at 
regular intervals and we are a point of contact for any queries. This is important 
to have especially for those patients who have switched from warfarin to a 
DOAC as the level of input from their healthcare professional is significantly 
reduced once they have been switched and this can be very unsettling for 
patients.”
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Is adherence an issue for 
patients on DOACs?
Adherence and  
DOACs
Section 5
The EHRA and NICE provide advice which suggests that adherence, 
known to be ≤80% for most drugs in daily practice10, requires vigilance 
and optimisation. That is why all means to optimise compliance should 
be considered10.
According to Sue Rhodes, 
“Adherence has always been an issue with any medication but 
the difference with the DOACs is that they are required to take every 
dose otherwise they are at risk of a stroke / further clot development. 
That is why it is imperative that full counselling is offered to patients 
commencing on these drugs in the same way that we would counsel 
regarding warfarin. Asking a patient to take a drug that may or may not 
prevent them from having a stroke is much more diffi cult than asking 
them to take the medication when they already have a condition (e.g. 
deep vein thrombosis/ pulmonary embolism) and the patient knows 
that it will get better [if they take the medication]. This has always been 
the case for warfarin, but we have the benefi t of being able to check 
compliance with warfarin.”
According to the AF Association, improvements have been made in 
the detection and protection of patients with AF, including medicines 
reviews. However, a gap remains of how to effectively communicate the 
value of anticoagulant therapy and its monitoring to patients. To ensure 
consistency in what is provided to patients on DOACs, the AF Association 
suggests a personalised package of care which includes:30,31 
• Stroke awareness and ways to prevent AF-related stroke
• Psychological support
• Contact details for further advice and support
• Comprehensive education
22
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support
Contact details 
for further advice 
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A dynamic process
Improving adherence requires a frank, open approach which accepts that 
non-adherence might be the norm and avoids blaming patients, encouraging 
them instead to communicate doubts and concerns about their treatment41. 
Often healthcare professionals are unaware of how patients take their 
medicines and sometimes patients do not take their medicines as prescribed.42 
For this reason, it is important to assess patients’ readiness to follow treatments, 
provide advice on how to do it and take the opportunity to monitor their 
progress on every appointment43. 
Informed adherence should be one of the goals of a dynamic, multidisciplinary, 
patient-centred approach. This should include specific training for healthcare 
professionals on how to manage adherence and how to adapt interventions to 
different patient needs43. 
 
For anticoagulation therapy on DOACs, Prof Camm suggests that education is 
the best way forward. He also explains: 
“Adherence and persistence are common problems, particularly with any 
therapy which prevents disease or complications when given for a condition 
which does not result in immediate improvement of symptoms. For most drugs 
it doesn’t matter too much if occasional doses are missed, for example, statins 
or antihypertensive therapy. This is not the case with drugs which have relatively 
short half-lives and which are life- or irretrievable harm–saving therapies. 
Adherence is therefore crucial and in the absence of adequate monitoring is 
hard to assess.”
Low-cost interventions
Low cost interventions on adherence can achieve significant cost-savings 
by focusing on the prevention of risk factors and adverse health outcomes44. 
Adherence can be improved with tailored interventions that take into account 
the specific difficulties the patient is experiencing45. 
In the next section, we look at what some anticoagulation services are doing to 
provide an excellent service and take action on adherence.
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Involve pharmacists in the 
improvement of adherence – 
the Perfect pathway 
Case 
study
NICE describes that pharmacists can have a role in supporting 
adherence by reinforcing “the importance of treatment and the need 
to take every prescribed dose each time they dispense the patient’s 
prescriptions”37. 
Anticoagulation care teams are already working in conjunction with 
pharmacists to conduct face-to-face medicine reviews and support 
adherence as part of an advance service called the new medicines 
service (NMS). This service aims to improve patient understanding of 
treatment and medicine concordance and it consists of structured 
interviews carried out by community pharmacist with patients during 
their first month of treatment with a new medicine.46
At a multidisciplinary meeting in 2015, Sue Rhodes and Sarah Bond 
from Great Western Hospital expressed concerns about the reduced 
follow-up they could provide for DOAC patients. Fiona Castle from 
the local pharmaceutical committee (LPC) expressed concern 
about the community pharmacists’ inability to identify patients early 
enough to provide follow-up through the NMS. As poor adherence 
for anticoagulants can result in potentially significant harm through 
ineffective treatment or side effects, these drugs are eligible for NMS. They 
agreed to work together to develop a referral scheme.46
The New Medicines Service and Great 
Western Hospital 
The anticoagulation team asked all new patients for details of their usual 
pharmacy and for permission to share information with them. Once they 
registered the information in PharmOutcomes, they began referring the 
patients to the NMS service, which emails the pharmacies and makes 
the information available in their system.46 
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Sue Rhodes, from Great Western Hospital, describes:
“One of the things that we explored was to involve the community pharmacist by 
linking with PharmOutcomes. We ask the patient which pharmacy they collect 
their regular medications from and each week we upload the information to the 
community pharmacies via PharmOutcomes. This then prompts the pharmacist 
to either contact the patient by phone to go over their new medication, or they 
will ask the patient to attend the pharmacy for a face-to-face discussion to 
reiterate the counselling points. The patient is also checked each time their 
medication is collected and asked about any problems. We have found this 
service extremely useful.”
Between October 2015 and January 2017, the anticoagulation service made 
526 referrals at an average of 33 patients a month. Of these, 72.8% referrals 
were acknowledged by the pharmacy and 59.1% marked as completed on 
the system. Patients were followed up through the NMS system in the majority 
of cases – informal follow-up through telephone, post-discharge medicines use 
review and discussions when patients visited the pharmacy, also took place. 
Pharmacists reported 88% of the referrals useful and the system is now fi rmly 
embedded.46
Sue Rhodes explains that,
“One hat does not fi t all, but we need to work with existing services to enable 
them to carry out the relevant follow-up. It doesn’t have to be complicated,
but it needs to be owned so that someone has responsibility for these patients. 
The system that we use in our clinic could easily be replicated in primary care.”
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Excellent anticoagulation 
service in a nurse-led DOAC 
clinic in primary care  
Case 
study
At a general practice surgery in Birmingham, a clinical nurse specialist 
(CNS)-led clinic was designed to manage patients receiving DOACs in 
primary care in a way which is safe, efficient and cost-effective47. 
The anticoagulation service at the GP surgery was already well-
established and managing 125 patients on VKAs using INRstar, a clinical 
decision support software, but there was no formal management or 
follow-up for DOAC patients47. 
Donna Sydenham, CNS at the Bellevue Medical Centre in Birmingham, 
explained:
“I recognised there was no structured follow-up in primary care for 
patients that had been initiated on DOAC medications. Once they are 
initiated, they are then discharged back to the GP. This was a concern 
because: a) compliance was not being checked and b) renal function 
was not being monitored – these could potentially lead to serious 
adverse events. I decided to develop a system at our clinic that ensured 
excellent patient care and safety.”
A list of patients taking DOACs was identified by the practice and 
added to INRstar for management and follow-up. All subsequent 
patients initiated on DOACs at the practice were also added to ensure 
appropriate management and support, and to facilitate the switching 
process from one anticoagulant to another47.
A patient-focused service
One of the main aims of this clinic was to create a patient-focused, 
holistic approach to implement NICE guidance on DOACs and make 
the service safe, cost-effective and efficient47. The initial consultation with 
the patient is an example of how this was achieved. 
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Comprehensive initial consultations
The appointment involves a detailed discussion of the indication and 
options for treatment, to include VKAs and DOACs, and the risks and benefi ts 
associated with each of the options in accordance with recommendations. The 
CNS took a holistic overview of the patient, taking into consideration lifestyle, co-
morbidities and other medications. The initial session also included a thorough 
discussion around the importance of adherence and a detailed overview of 
the way the patient currently takes their medications. This was important to 
ascertain if the patient is suitable for a DOAC.47
A clear pathway for structured follow-up
Phone reviews were the fi rst point of contact a month after DOAC initiation. The 
frequency of review after this is dependent on previous creatinine clearance 
results and includes at least an annual comprehensive review of liver and 
kidney function, weight, blood pressure and a full blood count.47
The clinic says that the CNS-led clinic has been successful resulting in fewer 
admissions to hospital and fewer adverse events. They also said that feedback 
has been positive from staff and patients and concluded that appointing a 
clinical-lead or CNS for anticoagulation in each practice can provide many 
benefi ts, including improved outcomes, better continuity of care and a more 
positive experience for patients.47
What can be done about 
adherence?
Supporting 
adherence
Section 6
Studies have been shown that some patients started questioning the 
benefi ts of anticoagulation therapy soon after initiation. One study 
suggested that 1 in 3 patients become non-persistent within 6 months48  
whilst another study showed that during the fi rst year, fewer than half of 
the patients took the medications consistently49. 
A multi-method approach that combines self-reporting and reasonable 
objective measures is the current state-of-the-art in the measurement of 
adherence17. Sue Rhodes suggests that one of the things that can be 
done is to “support practices in primary care who do currently provide 
a DOAC service by devising a way for them to accurately monitor these 
patients to ensure compliance, renal function and age are considered 
in order to maximise the appropriate dose for each patient.” 
Comprehensive education and integrated 
technology
The AF Association recommends that the personalised package for 
patients on DOACs should include the latest, comprehensive education 
and information on:50  
• cause
• effects and possible complications of AF
• management of rate and rhythm control
• anticoagulation (including practical advice to improve adherence) 
• provision of self-monitoring and support networks such as AF 
Association and Arrhythmia Alliance
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The AF Association also suggests that there needs to be a focus on how mobile 
technology can be used to help patients remain on therapy, by providing 
support and motivation, as well as connecting them to their clinician without 
the need for multiple GP appointments in already over-stretched services50. 
The AF Association explains that it has been at the forefront in working with new 
technologies to get them trialled by patients, producing data and pushing 
for the uptake of proven technologies. Their commitment continues: “we will 
do the same for technologies that enable patients to remain on therapy and 
connected to health reporting systems.”50
1 in 3 patients become non-
persistent within 6 months49  
Anticoagulation and an ageing 
population 
The future of 
anticoagulation therapy: 
fi ndings and conclusion
Section 7
Anticoagulants are one of the most frequently prescribed medications in 
elderly patients as the risk of thromboembolic complications that require 
anticoagulation therapy increases with age51. Dr Matthew Fay, Clinical 
Chief Executive The Westcliffe Group, explains that, 
“The frail patient is at a tipping point in the benefi ts of anticoagulation 
for stroke risk reduction. Although we know that this is a group with a 
very high stroke risk, we can also see that the reduction of the number 
of stroke events balances with the number of bleeding events.”
He raises questions about the care pathways when patients are not able 
to continue anticoagulation therapy with DOACs, 
“We can return to the older VKA intervention. This will now be in an older, 
frailer patient who is warfarin naïve. They will require close monitoring 
as warfarin is a challenging medication in those with poor renal 
function. Should this switch be done before the absolute value of 
creatinine clearance necessitating a change occurs, thus giving time 
for stabilisation before true renal decline?
Should intervention be discontinued at this stage? If so who is to make 
this decision and how can we support the patient to make an informed 
choice? Should this be left to the individual clinician with their patient 
or can the discussion be widened to include other experts such as 
anticoagulation therapists, elderly care specialists or community 
matrons, cardiology-interested practitioners working in a multidisciplinary 
team (MDT) setting to ensure all the various facets of the decision are 
appropriately reviewed to assist the patient (and often their carer) make 
a fully informed decision?”
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Sue Rhodes considered this and suggests,
“This is a dilemma, but I think adopting a MDT approach would work in some 
areas, perhaps a GP having a joint clinic with an anticoagulant specialist nurse 
to review the more elderly patients before a change is necessitated so that a 
discussion can begin with the patient outlining the options? In an area where 
anticoagulation may not be everyone’s interest, this could be a mini-specialist 
clinic where patients from other practices were seen.”
The need for more data
Dr Fay suggests research is necessary to discover safer ways to help patients 
through anticoagulation therapy well into old age and highlights the need of a 
secured system, “more work is required to research the best options for patients 
in this setting, but until clear evidence is available we need to ensure that both 
patients and their clinicians are in a safe and well-governed system.”
Prof Fuat suggests the need for “independent data collection for patients in 
the real world. This could be done through a practice-based registry where all 
clinical outcomes for patients receiving DOACs could be collected.” The AF 
Association is supporting efforts to use integrated mobile technology that can 
help patients remain on therapy and suggests that “apps that can educate 
and motivate patients, while connecting them to their doctor, and providing 
useful integrated feedback will be of signifi cant benefi t.”
Sue Rhodes explains,
“We have managed to do this in Swindon and I see no reason why it could not 
be accomplished in primary care, it just needs ownership and the support of a 
specialist (this could be a secondary anticoagulant clinic where advice could 
be sought).”
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“(...)more work is required 
to research the best options 
for patients in this setting, 
but until clear evidence is 
available we need to ensure 
that both patients and their 
clinicians are in a safe and 
well-governed system.”
Dr Matthew Fay, Clinical Chief Executive The Westcliffe Group
Conclusion
For patients taking long-term anticoagulation, the advent of the DOACs has 
opened the possibility of effective protection against stroke and VTE without 
many of the burdens of the treatment which the VKAs involved. For clinicians, 
the problems are changing from organising regular INR tests and adjusting 
warfarin doses, to ensuring that patients remain actively engaged, informed 
and adherent with their treatment. 
The evidence presented in this paper strongly suggests that the tools we 
need to achieve this aim are based on genuine joint decision making and 
an ongoing relationship which involves continuous support, education and 
learning both for patients and clinicians.
Patients needing anticoagulation form a heterogeneous group in which no 
single solution is appropriate for everyone. For many people, treatment with 
DOACs will be the optimum choice and in these cases, anticoagulation care 
teams will need to develop robust ways of monitoring patients and maximise 
treatment adherence. For a significant number of patients – particularly the 
very elderly – warfarin will still play a role. Better ways of providing convenient, 
safe dosing advice and monitoring will need to be developed for these.
Broadening the delivery of anticoagulation care to include healthcare 
professionals other than the traditional hospital/GP/nurse model will help 
deliver the multidisciplinary comprehensive care that patients need. In line with 
the NHS’ Five Year Forward View, another way forward will be to embrace the 
possibilities which technology52 can deliver for patients and their care teams. 
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